BG106450A - Приложение на ретигабин за лечение на невропатична болка - Google Patents

Приложение на ретигабин за лечение на невропатична болка

Info

Publication number
BG106450A
BG106450A BG06450A BG10645002A BG106450A BG 106450 A BG106450 A BG 106450A BG 06450 A BG06450 A BG 06450A BG 10645002 A BG10645002 A BG 10645002A BG 106450 A BG106450 A BG 106450A
Authority
BG
Bulgaria
Prior art keywords
neuropathic pain
retigabin
treating neuropathic
treating
ethoxycarbobylaminobenzenes
Prior art date
Application number
BG06450A
Other languages
English (en)
Other versions
BG65795B1 (bg
Inventor
Chris Rundfeldt
Reni Bartsch
Angelika Rostock
Christine Tober
Rita Dost
Original Assignee
Valeant Pharmaceuticals North America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valeant Pharmaceuticals North America filed Critical Valeant Pharmaceuticals North America
Publication of BG106450A publication Critical patent/BG106450A/bg
Publication of BG65795B1 publication Critical patent/BG65795B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретението се отнася до приложение на 2-амино-4-(4-флуорбензиламино)-1-етоксикарбониламинобензенс формула или негови фармацевтично приемливи солиза профилактика и лечение на невропатична болка.
BG106450A 1999-09-27 2002-02-27 Приложение на ретигабин за лечение на невропатична болка BG65795B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/406,135 US6117900A (en) 1999-09-27 1999-09-27 Use of retigabine for the treatment of neuropathic pain
PCT/EP2000/009284 WO2001022953A2 (de) 1999-09-27 2000-09-22 Verwendung von retigabin zur behandlung von neuropathischen schmerzen

Publications (2)

Publication Number Publication Date
BG106450A true BG106450A (bg) 2002-09-30
BG65795B1 BG65795B1 (bg) 2009-12-31

Family

ID=23606675

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106450A BG65795B1 (bg) 1999-09-27 2002-02-27 Приложение на ретигабин за лечение на невропатична болка

Country Status (35)

Country Link
US (1) US6117900A (bg)
EP (1) EP1223927B1 (bg)
JP (1) JP2003510273A (bg)
KR (1) KR100730829B1 (bg)
CN (2) CN100522155C (bg)
AR (1) AR026163A1 (bg)
AT (1) ATE288748T1 (bg)
AU (1) AU777764B2 (bg)
BG (1) BG65795B1 (bg)
BR (1) BR0014293A (bg)
CA (2) CA2659048A1 (bg)
CZ (1) CZ295980B6 (bg)
DE (1) DE50009504D1 (bg)
DK (1) DK1223927T3 (bg)
EE (1) EE05073B1 (bg)
ES (1) ES2237461T3 (bg)
HK (1) HK1052471A1 (bg)
HR (1) HRP20020234A2 (bg)
HU (1) HUP0202853A3 (bg)
IL (3) IL148309A0 (bg)
IS (1) IS6303A (bg)
MX (1) MXPA02003179A (bg)
NO (1) NO329744B1 (bg)
NZ (1) NZ517616A (bg)
PL (1) PL200847B1 (bg)
PT (1) PT1223927E (bg)
RS (1) RS50091B (bg)
RU (1) RU2264813C2 (bg)
SI (1) SI1223927T1 (bg)
SK (1) SK286057B6 (bg)
TR (1) TR200200706T2 (bg)
TW (1) TWI257304B (bg)
UA (1) UA72550C2 (bg)
WO (1) WO2001022953A2 (bg)
ZA (1) ZA200202449B (bg)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525062B2 (en) 2000-06-09 2003-02-25 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
US6348486B1 (en) 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
WO2002061075A1 (fr) * 2001-02-01 2002-08-08 Takeda Chemical Industries, Ltd. Proteine de recepteur couple aux proteines g et adn correspondant
WO2002072088A2 (en) 2001-02-20 2002-09-19 Bristol-Myers Squibb Company Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
AU2002338333A1 (en) * 2001-04-04 2002-10-21 Wyeth Methods for treating hyperactive gastric motility
EP1545535A4 (en) * 2002-09-05 2008-06-04 Scios Inc TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE
US20080039461A1 (en) * 2002-09-05 2008-02-14 Protter Andrew A Treatment of pain by inhibition of p38 map kinase
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
AU2003296954A1 (en) * 2002-12-13 2004-07-09 The Regents Of The University Of California Analgesic combination comprising nalbuphine
PT1578740E (pt) * 2002-12-27 2007-05-31 Lundbeck & Co As H Derivados de 1, 2, 4-triaminobenzeno úteis para tratamento de distúrbios do sistema nervoso central
PL377221A1 (pl) * 2002-12-27 2006-01-23 H. Lundbeck A/S Pochodne 1,2,4-triaminobenzenu
MXPA05010174A (es) * 2003-04-25 2005-11-08 Lundbeck & Co As H Derivados de indol e indolina sustituidos.
US7799832B2 (en) 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
PL2298766T3 (pl) 2005-03-03 2014-09-30 H Lundbeck As Preparaty farmaceutyczne zawierające podstawione pochodne pirydyny
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
SG174095A1 (en) * 2006-08-23 2011-09-29 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
BRPI0719590A2 (pt) * 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
CN101868443A (zh) 2007-09-20 2010-10-20 特拉维夫大学拉莫特有限公司 N-苯基邻氨基苯甲酸衍生物及其用途
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
CA2731008A1 (en) * 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Modified release formulation and methods of use
DE102009013611A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Festes Retigabin in nicht-kristalliner Form
DE102009013613A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
DE102009013612A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
IT1398282B1 (it) * 2009-07-30 2013-02-22 Difass S A Ora Farmapros S P A Composizione comprendente acido alfa-lipoico e carnosina per il trattamento della sindrome dell arto fantasma
US20110087650A1 (en) * 2009-10-06 2011-04-14 Johnson Controls Technology Company Creation and use of causal relationship models in building management systems and applications
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
RU2446795C1 (ru) * 2011-03-31 2012-04-10 Федеральное государственное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Министерства здравоохранения и социального развития Российской Федерации" ФГУ "МНИОИ им. П.А. Герцена "Минздравсоцразвития России" Способ предотвращения фантомного болевого синдрома после ампутации конечностей
CN102531966B (zh) * 2011-12-23 2013-07-24 山东创新药物研发有限公司 瑞替加滨的晶型d及其制备方法
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
CN103271899A (zh) * 2012-12-30 2013-09-04 北京阜康仁生物制药科技有限公司 瑞替加滨粉碎粒度在制剂中的应用
CN105919990A (zh) * 2016-06-29 2016-09-07 青岛云天生物技术有限公司 用于预防和治疗神经病理性疼痛的药物组合物及其用途
CN106176715A (zh) * 2016-06-29 2016-12-07 青岛云天生物技术有限公司 一种神经病理性疼痛治疗用药物组合物及其用途
US11369593B2 (en) 2017-07-14 2022-06-28 Texas Tech University System Functionalized pyridine carbamates with enhanced neuroprotective activity
EP3694833A4 (en) 2017-10-09 2021-06-30 Ramot at Tel-Aviv University Ltd. TRPV1 AND POTASIC IONIC CHANNEL MODULATORS AND THEIR USES

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use

Also Published As

Publication number Publication date
WO2001022953A3 (de) 2002-05-23
MXPA02003179A (es) 2003-08-20
NO20021418L (no) 2002-03-21
ATE288748T1 (de) 2005-02-15
HK1052471A1 (zh) 2003-09-19
CZ2002989A3 (cs) 2002-08-14
CA2659048A1 (en) 2001-04-05
DK1223927T3 (da) 2005-04-11
PL200847B1 (pl) 2009-02-27
NO329744B1 (no) 2010-12-13
ZA200202449B (en) 2003-03-26
CN100522155C (zh) 2009-08-05
IL148309A (en) 2007-12-03
ES2237461T3 (es) 2005-08-01
RU2264813C2 (ru) 2005-11-27
TWI257304B (en) 2006-07-01
EE200200145A (et) 2003-04-15
AU7906100A (en) 2001-04-30
IL148309A0 (en) 2002-09-12
IL187030A (en) 2011-06-30
AR026163A1 (es) 2003-01-29
BR0014293A (pt) 2002-05-21
CZ295980B6 (cs) 2005-12-14
NZ517616A (en) 2002-12-20
KR20020042691A (ko) 2002-06-05
UA72550C2 (en) 2005-03-15
HUP0202853A3 (en) 2003-10-28
YU20302A (sh) 2005-03-15
HRP20020234A2 (en) 2003-06-30
JP2003510273A (ja) 2003-03-18
CA2384504A1 (en) 2001-04-05
CN1409632A (zh) 2003-04-09
RS50091B (sr) 2009-01-22
AU777764B2 (en) 2004-10-28
BG65795B1 (bg) 2009-12-31
IL187030A0 (en) 2008-02-09
NO20021418D0 (no) 2002-03-21
CA2384504C (en) 2009-05-26
HUP0202853A2 (hu) 2002-12-28
EP1223927B1 (de) 2005-02-09
DE50009504D1 (de) 2005-03-17
EE05073B1 (et) 2008-10-15
SI1223927T1 (bg) 2005-08-31
KR100730829B1 (ko) 2007-06-20
SK286057B6 (sk) 2008-02-05
RU2002109240A (ru) 2004-01-10
IS6303A (is) 2002-03-18
CN101444498A (zh) 2009-06-03
SK2922002A3 (en) 2002-08-06
TR200200706T2 (tr) 2002-10-21
PT1223927E (pt) 2005-06-30
PL353393A1 (en) 2003-11-17
WO2001022953A2 (de) 2001-04-05
US6117900A (en) 2000-09-12
EP1223927A2 (de) 2002-07-24

Similar Documents

Publication Publication Date Title
BG106450A (bg) Приложение на ретигабин за лечение на невропатична болка
GB0005251D0 (en) Therapeutic compounds
HK1055721A1 (en) Compounds to treat alzheimer's disease.
GB0223040D0 (en) Therapeutic compounds
UA39936C2 (uk) 2-(2,6-дифторфеніл)-4-(2-етокси-4-трет-бутилфеніл)-2-оксазолін, спосіб мiтицидної обробки та мiтицидна композиція
BG106586A (bg) Пиразолопиримидини като терапевтични средства
NZ237023A (en) 17beta-substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions
GB0225475D0 (en) Therapeutic agents
IL175398A0 (en) Steroidal compounds and pharmaceutical compositions containing them for treating oxidative stress and inflammation
PL310474A1 (en) Application of rilusole in treating neuro-aids diseases
MY119375A (en) Treatment of tinnitus using neuroprotective agents
PT1071422E (pt) Associações de riluzole e levodopa para o tratamento da doença de parkinson
EP1171428A4 (en) FAB I INHIBITORS
IL126235A0 (en) Compounds with growth hormone releasing properties
SE0101082D0 (sv) Novel use
BG105008A (bg) Производни на хигромицин а
TWI262791B (en) 6-methoxy-2-naphthylacetic acid prodrugs
WO2002058680A3 (en) Use of bicylic amino acids for preventing and treating visceral pain and gastrointestinal disorders
PT1049672E (pt) Derivados de azetidinocarboxamida para o tratamento de disturbios do snc
GB9904252D0 (en) Composition for the treatment of pain
PT1049670E (pt) Derivados de azetidinocarboxamida para o tratamento de perturbacoes do snc
ZA982808B (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
GB9918000D0 (en) Compositions for the treatment of pain
ATE323486T1 (de) Verwendung des riluzols oder dessen salzen zur phophylaxe und behandlung der adrenoleukodystrophie